Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in South Korea / NCT07442500
Starting soon Observational

Drug Coated Balloon vs. Drug-eluting Stent in Patients With Coronary Artery Disease

NCT07442500 · tracked via the Priya Life Science South Korea tracker
Sponsor
Samsung Medical Center
Phase
Observational
Started
2026-02-28
Last updated
2026-03-02

Condition(s) studied

Coronary Artery DiseasePercutaneous Coronary Intervention (PCI)

Investigational drug(s) / intervention(s)

Drug coated balloonDrug-eluting stent

Drug coated balloon: Patients receiving drug coated balloon angioplasty for de novo coronary artery disease

Drug-eluting stent: Patients receiving drug-eluting stent implantationfor de novo coronary artery disease

Study summary

Studies exploring the feasibility of drug-eluting balloon (DCB) in de-novo coronary lesions are limited. There are scarce data comparing DCB with drug-eluting stent (DES) in patients with high bleeding risk (HBR), a situation in which long-term maintenance of dual antiplatelet therapy (DAPT) is a clinical dilemma. This target trial emulation aims to compare clinical outcomes between DCB angioplasty and conventional DES implantation in de-novo coronary lesions in patients with coronary artery disease.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients with coronary artery disease undergoing percutaneous coronary intervention * Used devices number less than three (relatively simple lesion) Exclusion Criteria: * Hybrid strategy (DCB and DES use) * Failed percutaneous coronary intervention * Previous revascularization procedure before index percutaneous coronary intervention

Primary outcome measure(s)

  • Rates of MACCE (major adverse cardiac and cerebrovascular events) — 3 years after index procedure
    all-cause death, myocardial infarction, revascularization, and stroke

Trial sites (1)

FacilityCityRegionStatus
Samsung Medical Center Seoul South Korea

More Samsung Medical Center trials in South Korea

Prospective Pecutaneous Coronary Intervention Registry Recruiting
Radiotherapy Dose Adaptation Based on Tumor Biology in Patients With cN2b-N3 Breast Cancer Recruiting
Clinical Application of Genetic Sequencing of Early Gastric Cancer and Gastric Adenoma Patients Recruiting
INsTantenous wavE-Free Ratio-guided PCI Versus Fractional Flow REserve-Guided PCI in rouTine Clinical Practice, Prospective, Multicenter Registry Active, not recruiting
Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism Starting soon

Other trials for the same condition

Prospective Pecutaneous Coronary Intervention Registry Recruiting
AI-Powered Electrocardiography for Diagnosis and Prognostic Prediction in Cardiovascular Disease (AI-CVD): Multicenter Retrospective Study Recruiting
STabilization of Atheroma by Lipid-reducing Effect of Drug-Coated Balloon (STABLE-DCB) Recruiting
Evaluation of Effectiveness and Safety of Xience Skypoint Stents in Routine Clinical Practice Recruiting
The DECISION-CTO Extended 10 Y Follow-up Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07442500 on ClinicalTrials.gov ↗ ← All trials in South Korea